Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.58 |
| ▸ | STS | P08842 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | TEK | Q02763 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16114228 | 1.00 | CYP19A1 (0.58) | CYP19A1STSKDRTEKPDE4B | |
| SCHEMBL16044173 | 0.91 | CYP19A1 (0.58) | CYP19A1STSKDRTEKPDE4B | |
| SCHEMBL16044339 | 0.89 | CYP19A1 (0.55) | CYP19A1STSKDRTEKPDE4B | |
| SCHEMBL29501207 | 0.87 | CYP19A1 (0.45) | CYP19A1STSPDE4B | |
| SCHEMBL16044180 | 0.86 | CYP19A1 (0.55) | CYP19A1STSKDRTEKPDE4B | |
| SCHEMBL29501214 | 0.86 | PDE4B (0.48) | CYP19A1KDRTEKPDE4BCA2 | |
| SCHEMBL16046874 | 0.86 | PDE4B (0.48) | CYP19A1KDRTEKPDE4BCA2 | |
| SCHEMBL16075854 | 0.84 | CYP19A1 (0.40) | CYP19A1KDRTEKPDE4BEPHB4 | |
| SCHEMBL16075840 | 0.83 | HDAC1 (0.41) | CYP19A1KDRTEKPDE4BEPHB4 | |
| SCHEMBL16075839 | 0.83 | HDAC1 (0.41) | CYP19A1KDRTEKPDE4BEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2025-04-17 | — | — | US | disclosed |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | CYP19A1 2066/4885STS 4308/4885KDR 840/4885 |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | CYP19A1 2066/4885STS 4308/4885KDR 840/4885 |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | CYP19A1 2107/4885STS 4307/4885KDR 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.